canada clinical guidance

Urticaria and angioedema (non-anaphylaxis)

A Canadian clinical summary of urticaria and angioedema (non-anaphylaxis), with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by Urticaria. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:Canadian urticaria guide 2024

Source-attributed clinical priorities

  • First distinguish isolated urticaria or angioedema from anaphylaxis and from bradykinin-mediated angioedema.
  • Use a non-sedating antihistamine strategy for uncomplicated histaminergic urticaria and avoid routine corticosteroid dependence.
  • Escalate airway, breathing or circulation features immediately and refer recurrent angioedema without hives for specialist assessment.
  • Individual wheals usually resolve within 24 hours; fixed painful or bruising lesions suggest another disorder.
sources for this section:Canadian urticaria guide 2024

Practical assessment and management workflow

1
Establish acute versus chronic course, lesion duration, angioedema, triggers, medicines, infections and inducible patterns.
2
Assess airway and circulation before focusing on skin and avoid broad allergy panels without a specific hypothesis.
3
Use a non-sedating antihistamine strategy and remove a plausible trigger where one exists.
4
Review chronic refractory disease for step-up treatment and specialist assessment.
sources for this section:Canadian urticaria guide 2024

Safety, red flags and urgent escalation

  • Tongue or laryngeal swelling, wheeze, hypotension or multisystem reaction needs anaphylaxis treatment.
  • Angioedema without wheals in a patient taking an ACE inhibitor requires drug review and airway caution.
  • Avoid routine long courses of systemic corticosteroid for chronic urticaria.
sources for this section:Canadian urticaria guide 2024

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:Canadian urticaria guide 2024

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:Canadian urticaria guide 2024

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Allergy, Asthma & Clinical ImmunologyUrticaria2024;20(Suppl 3):64; DOI 10.1186/s13223-024-00931-6 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.